Neuroendocrine manifestations in Sjogren's syndrome

Rheumatic Disease Clinics of North America

Volumn 26, Issue 4, 2000, Pages 927-949

  Johnson, Elizabeth O ^a   Skopouli, Fotini N ^b   Moutsopoulos, Haralampos M ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b HAROKOPIO UNIVERSITY   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; ESTROGEN; GLUCOCORTICOID; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 6; MINERALOCORTICOID RECEPTOR; PROGESTERONE; PROLACTIN; RETINOIC ACID RECEPTOR; RIBONUCLEOPROTEIN; SEX HORMONE; TESTOSTERONE; THYROID HORMONE; THYROID HORMONE RECEPTOR; VITAMIN D RECEPTOR;

AUTOIMMUNE DISEASE; CORTICOSTEROID THERAPY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; NEUROENDOCRINOLOGY; NEUROIMMUNOLOGY; NEUROPSYCHIATRY; PRIORITY JOURNAL; REVIEW; SJOEGREN SYNDROME; STRESS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; THYROID GLAND;

GONADAL STEROID HORMONES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; SJOGREN'S SYNDROME; STRESS, PSYCHOLOGICAL; THYROID GLAND;

EID: 0033626431     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70177-0     Document Type: Article

References (105)

1. Estrogen induces the development of autoantibodies and promotes salivary gland lymphoid infiltrates in normal mice
2. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis and other rheumatic diseases
3. Primary Sjogren's syndrome in men
4. Corticosteroid therapy
5. The immunology of prolactin
6. Dexamethasone modulated protein synthesis in polymorphonuclear leukocytes: Response in rheumatoid arthritis
7. An association of fibromyalgia with primary Sjogren's syndrome: A prospective study of 72 patients
8. Relationship between sex hormones and disease activity in patients with primary Sjogren's syndrome
9. Activating and 'anxiogenic' effects of corticotropin-releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone
10. Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty
11. Chronic fatigue syndrome and a disorder resembling Sjogren's syndrome: Preliminary report
12. Oestradiol- and testosterone-mediated effects on the immune system in normal and autoimmune mice are genetically linked and inherited as dominant traits
13. Pituitary-adrenal axis responsiveness to ovine CRH in patients with rheumatoid arthritis treated with low-dose prednisone
14. Endocrine end-points in rheumatoid arthritis
15. Hypothalamic-pituitary mediated modulation of immune function: Prolactin as a neuroimmune peptide
16. Reciprocal interactions between the neuroendocrine and immune systems
17. Abnormal neuroendocrine immune communications in patients with rheumatoid arthritis
18. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation
19. The concepts of stress and stress system disorders: Overview of physical and behavioral homeostasis
20. High prevalence of subclinical Sjogren's syndrome features in patients with autoimmune thyroid disease
21. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: Failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis
22. Prevalence of Sjogren's syndrome in a closed rural community
23. Disease associations with complotypes, supratypes and haplotypes
24. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome
25. Recent insight into the structure and function of the glucocorticoid receptor
26. Nandrolone decanoate (deca-durabolin) in primary Sjogren's syndrome: A double blind pilot study
27. Neuropsychiatric abnormalities in primary Sjogren's syndrome
28. Long-term low-dose glucocorticoid therapy associated with remission of overt renal tubular acidosis in Sjogren's syndrome
29. The steroid and thyroid hormone receptor superfamily
30. Primary Sjogren's syndrome in the elderly: Clinical and immunological characteristics
31. Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress (1)
32. Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress (2)
33. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease
34. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome
35. Salivary and serum interleukin 6 in primary Sjogren's syndrome
36. Hypothalamic-pituitary-adrenal axis function and prolactin secretion in systemic lupus erythematosus
37. The prevalence of hyperprolactinemia in patients with primary Sjogren's syndrome
38. The endocrine thymus
39. Gastrointestinal manifestations of endocrine disease
40. Reduction in the risk of rheumatoid arthritis among women who take oral contraceptives
41. Corticosteroids in rheumatoid arthritis
42. Clinical and pathological features of Sjogren's syndrome associated with autoimmune thyroid diseases
43. Estrogen deficiency accelerates autoimmune exocrinopathy in murine Sjogren's syndrome through fas-mediated apoptosis
44. Some aspects of the H-2 system, the major histocompatibility system in the mouse
45. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjogren's syndrome
46. Dry eyes or mouth. An epidemiological study in Swedish adults with special reference to primary Sjogren's syndrome
47. Prolactin, immunoregulation and autoimmune diseases
48. Neuroimmunological axis and rheumatic diseases
49. Mechanisms of stress: A dynamic overview of hormonal and behavioral homeostasis
50. Hypofunction of the stress axis in Sjogren's syndrome
51. Effect of altered thyroid hormone levels on hypothalamic-pituitary-adrenal function
52. Effect of short and long duration hypothyroidism and hyperthyroidism on hypothalamic corticotropin-releasing hormone mRNA responses to stress
53. Effects of short and long duration hypothyroidism and hyperthyroidism on the plasma adrenocorticotropin and corticosterone responses to ovine corticotropin-releasing hormone in rats
54. Thyroid disease in Sjogren's syndrome
55. Cortisol catabolism by lymphocytes of patients with systemic lupus erythematosus and rheumatoid arthritis
56. Estradiol and testosterone in minor salivary glands of Sjogren's syndrome
57. Sex and age in systemic lupus erythematosus
58. Low plasma androgens in women with systemic lupus erythematosus
59. Development of thyroid disease in patients with primary and secondary Sjogren's syndrome
60. Neuropsychiatric dysfunction in primary Sjogren's syndrome
61. Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjogren's syndrome
62. Perturbations of hypothalamic-pituitary-gonadal (HPG) axis and adrenal androgen (AA) functions in rheumatoid arthritis
63. Perturbations of hypothalamic-pituitary-gonadal axis and adrenal androgen functions in rheumatoid arthritis: An odyssey of hormonal relationships to the disease
64. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans
65. A study of serum androgen and cortisol levels in female patients with rheumatoid arthritis. Correlation with disease activity
66. Primary Sjogren's syndrome in men. Clinical, serologic and immunogenetic features
67. Sjogren's syndrome: Autoimmune epithelitis
68. Sjogren's syndrome therapy: Future directions
69. In vitro effect of thymosin on T-lymphocyte rosette formation in rheumatic diseases
70. Sjogren's syndrome
71. Adrenal secretion of cortisol in patients with rheumatoid arthritis
72. Bromocriptine microcapsules inhibit ornithine decarboxylase activity induced by Freund's complete adjuvant in lymphoid tissues of male rats
73. The secretion rate of cortisol in patients with rheumatoid arthritis
74. Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat
75. Modes of epithelial cell death and repair in Sjogren's syndrome
76. Thyroid gland disorders in primary Sjogren's syndrome
77. Glucocorticoids inhibit estradiol-mediated uterine growth: Possible role of the uterine estradiol receptor
78. Molecular analysis of HLA class II genes in primary Sjogren's syndrome. A study of Israeli and Greek non Jewish patients
79. Prolactin receptors on human T and B lymphocytes: Antagonism of prolactin binding by cyclosporine
80. Glucocorticoid receptors in rheumatoid arthritis
81. The syndrome of hypopituitarism
82. Sjogren's syndrome associated with pigmentation and scleroderma of the legs
83. Cytokines in Sjogren's syndrome
84. Obstetric and gynaecological profile in patients with primary Sjogren's syndrome
85. IL-6 stimulates anterior pituitary hormone release in vitro
86. Hypoimmune fatigue syndromes: Diseases of the stress response?
87. A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall arthritis in Lewis rats
88. Corticotropin releasing hormone related behavioral and neuroendocrine responses to stress in Lewis and Fischer rats
89. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis susceptible Lewis rats
90. The stress response and the regulation of inflammatory disease
91. Keratoconjunctivitis sicea and Sjogren's syndrome
92. Androgens and dry eye in Sjogren's syndrome
93. Identification and characterization of CRISP-3 mRNA transcripts in minor salivary glands from patients with Sjogren's syndrome
94. Vasculitis in primary Sjogren's syndrome: Histologic classification and clinical presentation
95. Can oestrogens be used as adjuvant therapy in female patients with rheumatoid arthritis?
96. Estrogen, progesterone, and tesosterone: Can they be used to treat autoimmune diseases?
97. Evidence for hypothalamic CRH deficiency in patients with seasonal affective disorder
98. Effects of ethinylestradiaol on the course of spontaneous autoimmune disease in NZB/W and NOD mice
99. Malignant lymphoma in primary Sjogren's syndrome
100. Prolactin and autoimmune disease
101. Corticosteroid metabolism and rheumatoid arthritis
102. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus
103. Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis
104. Neuroendocrine hormonal factors in rheumatoid arthritis and related conditions